ArticleCellular and molecular gastroenterology and hepatology2026
Bile Acid Detergency as Determinant of Liver Pathology in a Humanized Mouse Model of Progressive Familial Intrahepatic Cholestasis Type 3.
Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsProgressive familial intrahepatic cholestasis type 3 (PFIC3) is caused by impaired activity of ABCB4 that transports phosphatidylcholines (PC) from hepatocytes into bile. Abcb4-knockout (KO) mice have been generated, but hydrophilic muricholic acids in their bile acid (BA) pool may limit pathology and thereby hamper translation to human PFIC3. Therefore, we addressed whether Abcb4 knockdown (Abcb4-KD) in the livers of Cyp2c70-KO mice with a human-like BA composition leads to liver pathology that more closely resembles human PFIC3.
methodsExpression of Abcb4 gene was suppressed in livers of Cyp2c70-KO/L-Cas9tg mice and control-Cas9tg mice using CRISPR/Cas9-technology to assess short- and long-term consequences. The BA sequestrant colesevelam was mixed into the chow diet (2% w/w) of Cyp2c70-KO mice with or without Abcb4-KD, and the effects were evaluated after 6 weeks.
resultsAbcb4-KD strongly reduced biliary phospholipid:BA ratios in both Cyp2c70-KO and control mice. However, plasma transaminases elevations, liver fibrosis, and ductular reactions were markedly aggravated by Abcb4-KD in the context of a human-like BA composition. Importantly, the biliary lipid compositions differed markedly between the 2 Abcb4-KD models. Reduced biliary PC and increased concentrations of lysophosphatidylcholine, sphingomyelin, and ceramide were associated with the severity of liver disease only in Cyp2c70-KO/Abcb4-KD mice. Gene set enrichment analysis indicated that epithelial-mesenchymal transition was induced in the livers of Cyp2c70-KO/Abcb4-KD mice compared with control Abcb4-KD mice. BA sequestration reduced biliary BA secretion rates and mitigated liver pathology in Cyp2c70-KO/Abcb4-KD mice.
conclusionsThe presence of a human-like BA composition profoundly aggravates liver pathology upon Abcb4 reduction in mice, conceivably due to the augmented extrusion of non-PC phospholipids by hydrophobic BAs from membranes into bile. This humanized PFIC3 model is anticipated to accelerate the development of novel therapies for PFIC3 and potentially other cholestatic liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.